# RA Capital Management

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/ra-capital-management
Canonical HTML page: https://getbiobrief.com/entity/ra-capital-management

## Recent coverage (1 stories)

### Neridronate Phase 3 Backed by $150M Merger and Financing
2026-08-22 01:36:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Neridronate, an investigational CRPS-1 bisphosphonate already approved in Italy, moves into a 270-patient pivotal CRPS-RISE Phase 3 with FDA Breakthrough, Fast Track, and Orphan designations. The all-stock Werewolf-Ambros merger and oversubscribed $150 million private placement fund development through topline in 2028.
Full story: https://getbiobrief.com/story/neridronate-phase3-150m-merger-financing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.